November 6, 2025 – The "2025 Sichuan Top 100 Private Enterprises Release Conference and Prominent Sichuan Entrepreneurs’ Luzhou Tour" event, jointly organized by the Sichuan Provincial Federation of Industry and Commerce (General Chamber of Commerce), the CPC Luzhou Municipal Committee, and the Luzhou Municipal People's Government, was successfully held in Luzhou.

During the conference, the Sichuan Provincial Federation of Industry and Commerce released four key lists: the 2025 Sichuan Top 100 Private Enterprises, the Top 100 in Manufacturing, the Top 50 in Services, and the Top 100 by R&D Investment. Simultaneously, the "2025 Sichuan Top 100 Private Enterprises Research and Analysis Report" was issued. The report highlights six major developmental strengths of the 2025 Top 100 private enterprises: a continuously rising entry threshold, the prominent leading role of the manufacturing sector, deepening transformation and upgrading, accelerating technological innovation, orderly progress in corporate internationalization, and the active fulfillment of social responsibilities.

Since initiating its strategic shift from generic drugs to innovative drugs in 2011, Sichuan Biokin Pharmaceutical Co., Ltd. has focused on cutting-edge fields with high technical barriers, such as Antibody-Drug Conjugates (ADCs). Leveraging its sustained transformation and innovative capabilities, the company was concurrently selected for three prestigious lists: the "2025 Sichuan Top 100 Private Enterprises," the "2025 Sichuan Top 100 Manufacturing Private Enterprises," and the "2025 Sichuan Top 100 Private Enterprises by R&D Investment."

Looking ahead, with the deepening implementation of the "Healthy China" strategy, innovative enterprises like Biokin Pharmaceutical will be driven by technological breakthroughs and industrial upgrading. They are poised to contribute to the higher-quality development of Sichuan's biopharmaceutical industry and provide more "Made-in-China" innovative solutions for patients worldwide.